Moleculin Biotech, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Research and development | $15.9M | $17.7M | $19.5M | $19.0M | $14.4M |
| Operating expenses | $25.1M | $26.6M | $29.6M | $30.6M | $23.0M |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M |
| Pretax income | -$33.6M | -$26.0M | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.6M | -$26.0M | -$29.8M | -$29.0M | -$15.9M |
| Balance Sheet | |||||
| Cash and equivalents | $8.9M | $4.3M | $23.6M | $43.1M | $70.9M |
| Current assets | $9.7M | $5.2M | $26.3M | $45.6M | $72.5M |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M |
| Current liabilities | $6.9M | $5.4M | $6.8M | $4.8M | $3.6M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M |
| Stockholders' equity | $15.0M | $11.2M | $30.9M | $52.2M | $79.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M |
| Depreciation and amortization | $90,000 | $126,000 | $127,000 | $130,000 | $164,000 |
| Stock-based compensation | $1.7M | $1.7M | $2.0M | $2.3M | $2.4M |
| Capital expenditure | $0 | $13,000 | $124,000 | $67,000 | $19,000 |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M |
Shares outstanding 5.3M · Free float 99.0%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.